Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-Remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableWithdrawnNCT04261556
What this trial is testing

TDCS to Enhance Cognitive Training in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University of Milano Bicocca
Early research (Phase 1)Study completedNCT02193217
What this trial is testing

Explore the Cardiac Pharmacodynamics of MT-1303

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Tanabe Pharma Corporation 81
Testing effectiveness (Phase 2)Ended earlyNCT00595920
What this trial is testing

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingClinically Isolated Syndrome
Opexa Therapeutics, Inc. 116
Large-scale testing (Phase 3)Study completedNCT01462318
What this trial is testing

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 133
Post-approval studies (Phase 4)Study completedNCT01930708
What this trial is testing

A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes

Who this might be right for
Relapsing-Remitting Multiple SclerosisMultiple Sclerosis
Biogen 1,114
Not applicableStudy completedNCT05218317
What this trial is testing

Evaluation of Relapse Presence in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis Relapse
Marmara University 87
Testing effectiveness (Phase 2)Study completedNCT01433250
What this trial is testing

Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Novartis Pharmaceuticals 39
Post-approval studies (Phase 4)Study completedNCT02419378
What this trial is testing

Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University Hospital Muenster 15
Not applicableStudy completedNCT07000968
What this trial is testing

The Effect of Task-Oriented Training and Virtual Reality Training on Balance, Gait and Fatigue in Individuals With Multiple Sclerosis

Who this might be right for
Multiple SclerosisBalance Impairment, Gait Disorders, FatigueMultiple Sclerosis Bening+1 more
Inonu University 63
Not applicableStudy completedNCT01925690
What this trial is testing

Development of a Motivational Intervention to Improve Treatment Adherence in MS

Who this might be right for
Relapsing-remitting Multiple Sclerosis
University of Missouri, Kansas City 80
Testing effectiveness (Phase 2)Study completedNCT01450124
What this trial is testing

Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Universitätsklinikum Hamburg-Eppendorf 29
Not applicableStudy completedNCT02308670
What this trial is testing

Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
University at Buffalo 150
Post-approval studies (Phase 4)Study completedNCT02205489
What this trial is testing

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Genzyme, a Sanofi Company 58
Not applicableLooking for participantsNCT04604041
What this trial is testing

Investigation of Subclinical Markers of Multiple Sclerosis

Who this might be right for
Multiple SclerosisRelapsing Remitting Multiple Sclerosis
University of Split, School of Medicine 50
Not applicableStudy completedNCT01485003
What this trial is testing

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 231
Not applicableNot Yet RecruitingNCT07724093
What this trial is testing

Effects of Powered Hip Flexion Device in Persons With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis (MS) Relapsing Remitting
University of Dayton 10
Early research (Phase 1)Ended earlyNCT01318421
What this trial is testing

ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Elan Pharmaceuticals 12
Large-scale testing (Phase 3)Study completedNCT02579681
What this trial is testing

Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 221
Post-approval studies (Phase 4)Study completedNCT00315367
What this trial is testing

A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Neurognostics 26
Large-scale testing (Phase 3)Study completedNCT00306592
What this trial is testing

Natalizumab Re-Initiation of Dosing

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 404
Next Page